PSMA radioligand therapy is a promising new class of therapy for prostate cancer. Heterogeneity of PSMA expression is an important factor explaining variability in clinical results. The ability to visualize the target with theranostics provides unique mechanistic insights. Potential clinically applicable strategies to improve patient selection and optimize therapeutic efficacy are discussed.
CITATION STYLE
Ravi Kumar, A. S., & Hofman, M. S. (2020). Mechanistic Insights for Optimizing PSMA Radioligand Therapy. Clinical Cancer Research, 26(12), 2774–2776. https://doi.org/10.1158/1078-0432.CCR-20-0209
Mendeley helps you to discover research relevant for your work.